Magnetic resonance imaging (MRI) may be superior to computed tomography for radiographic surveillance following laparoscopic renal cryoablation of renal masses, researchers reported at the World Congress of Endourology in Chicago.
SAN FRANCISCO—For the first time, clinicians may have an imaging tool that can help distinguish clear cell renal cell carcinoma (RCC) from other kinds of renal masses.
The FDA has approved Cysview (hexaminolevulinate HCl), an optical imaging agent indicated for use in the cystoscopic detection of non-muscle-invasive papillary bladder cancer in patients suspected or known to have lesions on the basis of prior cystoscopy.
ProUroCare Medical, Inc., of Minneapolis, Minn., has filed a de novo application with the FDA seeking marketing clearance for its prostate mechanical imaging (PMI) device (ProUroScan).
In an interview with Renal & Urology News, Robert D. Kreisman, JD, of Kreisman Law Offices in Chicago, shares some insights on legal issues related to imaging tests.
This article is the second in a two-part series on the expanding use of imaging studies.
Toronto-based hybridyne Imaging Technologies has received FDA clearance for ProxiScan, a high-resolution gamma camera for detecting cancer and other abnormalities.
This article is the first in a two-part series examining the expanding use of diagnostic imaging in urology.
TAMPA, Fla.—Cryoablation guided by magnetic resonance (MR) imaging is safe and effective for treating solid renal tumors, even those up to 7 cm in diameter, according to new data presented here at the Society of Interventional Radiology annual meeting. The technique could be an alternative to partial or total surgical resection.
Computed tomography (CT) images generally provide an accurate assessment of the size of renal tumors, researchers have concluded.
